Richter Gedeon Rt.

Chemical Works of Richter Gedeon is a multinational pharmaceutical company that is engaged in the research, development, production and marketing and trade of pharmaceutical products. Co.'s activities are divided into two major business segments: Pharmaceutical, including research, development and manufacturing of pharmaceutical products; and Wholesale and Retail including wholesale and retail trade through the distribution chain as well as marketing of its products. Co. is primarily engaged in production of gynecological, cardiovascular and gastroenterological products, antibiotics, antimicotics, OTC and medicines for treatment of the central nervous system.
  • TickerRICHTER
  • ISINHU0000123096
  • ExchangeBudapest Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryHungary

Gedeon Richter confirmed at HOLD, TP HUF 7,500 - Model update: Cautious guidance despite positive outlook for Vraylar

We have updated our financial projections by taking into account the recently released 2Q 20 results and the updated 2020 management guidance. Our DCF-based valuation yields an only 7% higher 12-month target price of HUF 7,500, hence we reiterate our HOLD recommendation for Gedeon Richter.

Raiffeisen Centrobank Equity Daily 04.08.2020

 AT: AT&S - 1Q 20/21 sales and EBITDA above expectations due to FX, net below, 2Q outlook: sales flat, EBITDA in 20-25% range (neutral)  CZ: Komercni Banka - Conference call take-aways (neutral)  HU: Gedeon Richter - Richter received marketing authorization for a new product in the UK (neutral)  HU: MOL - July model refining margins turned positive, while petchem margins stayed under pressure (neutral)  HU: Wizz Air - July capacity utilization at 74% and 61% load factor (neutral)  PL: Alior Bank - Changed 1H 20 reporting date (neutral)  PL: LPP - Preliminary 2Q operating l...

Gedeon Richter Company News - 2Q 20 Conference Call Notes

FY 2020 guidance The management updated its guidance, seeing now flat yoy revenues (in EUR terms) as a result of sales pressure in some markets (i.e. Russia, Romania, China), unfavourable FX (HUF appreciation against EUR, USD, RUB, RON), low doctor-patient contacts due to covid-19 restrictions, low level of inventories at wholesalers. Sales of Vraylar in the US are expected at USD 1.18 bn, which is fully based on the guidance of its US partner AbbVie. The detailed guidance is presented in the table below. At the same time, operating margin guidance was lifted by 1%p mainly as a result of lower...

Raiffeisen Centrobank Equity Daily 03.08.2020

 AT: Addiko Bank - Brandes reducing the stake to

Equity Weekly 300720

Company Events: (* preview included in the Equity Weekly) Friday, 31/07/2020 AT: Andritz, 2Q Earnings Release* AT: DO & CO, AGM AT: Erste Group, 2Q Earnings Release* HR: Valamar Riviera, 2Q Earnings Release* AT: Zumtobel, Dividend Payment (EUR 0.10) Monday,03/08/2020 RO: BRD-GSG, 2Q Earnings Release* HU: Gedeon Richter, 2Q Earnings Release* CZ: Komercni Banka, 2Q Earnings Release* Tuesday, 04/08/2020 AT: AT&S, 1Q Earnings Release* Wednesday, 05/08/2020 PL: Bank Pekao SA, 2Q Earnings Release* PL: Kety, 2Q Earnings Release AT: Lenzing, 2Q Earnings Release* HU: Magyar Telekom, 2Q Earnings...

Dave Nicoski ...
  • Ross LaDuke

Int'l Insights: Bullish Stocks

Concerns over perceived central bank policy missteps have been somewhat alleviated following dovish takeaways from Fed Chair Powell's comments, proclaiming interest rates are “just below” the neutral rate, and reminding everyone that future rate hikes are not predetermined. While this is certainly an incrementally positive development, it does not completely remove the specter of future rate hikes from our list of concerns. Of course, trade remains an issue despite optimism surrounding the Trump/Xi meeting at the G20 summit this week. Therefore, our outlook remains cautious and we expect c...

Chemical Works Of Gedeon Richter: 1 director sold

A director at Chemical Works Of Gedeon Richter sold 3,000 shares at 6,234.000HUF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...

Gedeon Richter confirmed at HOLD, TP HUF 7,500 - Model update: Cautious guidance despite positive outlook for Vraylar

We have updated our financial projections by taking into account the recently released 2Q 20 results and the updated 2020 management guidance. Our DCF-based valuation yields an only 7% higher 12-month target price of HUF 7,500, hence we reiterate our HOLD recommendation for Gedeon Richter.

Raiffeisen Centrobank Equity Daily 04.08.2020

 AT: AT&S - 1Q 20/21 sales and EBITDA above expectations due to FX, net below, 2Q outlook: sales flat, EBITDA in 20-25% range (neutral)  CZ: Komercni Banka - Conference call take-aways (neutral)  HU: Gedeon Richter - Richter received marketing authorization for a new product in the UK (neutral)  HU: MOL - July model refining margins turned positive, while petchem margins stayed under pressure (neutral)  HU: Wizz Air - July capacity utilization at 74% and 61% load factor (neutral)  PL: Alior Bank - Changed 1H 20 reporting date (neutral)  PL: LPP - Preliminary 2Q operating l...

Gedeon Richter Company News - 2Q 20 Conference Call Notes

FY 2020 guidance The management updated its guidance, seeing now flat yoy revenues (in EUR terms) as a result of sales pressure in some markets (i.e. Russia, Romania, China), unfavourable FX (HUF appreciation against EUR, USD, RUB, RON), low doctor-patient contacts due to covid-19 restrictions, low level of inventories at wholesalers. Sales of Vraylar in the US are expected at USD 1.18 bn, which is fully based on the guidance of its US partner AbbVie. The detailed guidance is presented in the table below. At the same time, operating margin guidance was lifted by 1%p mainly as a result of lower...

Raiffeisen Centrobank Equity Daily 03.08.2020

 AT: Addiko Bank - Brandes reducing the stake to

Equity Weekly 300720

Company Events: (* preview included in the Equity Weekly) Friday, 31/07/2020 AT: Andritz, 2Q Earnings Release* AT: DO & CO, AGM AT: Erste Group, 2Q Earnings Release* HR: Valamar Riviera, 2Q Earnings Release* AT: Zumtobel, Dividend Payment (EUR 0.10) Monday,03/08/2020 RO: BRD-GSG, 2Q Earnings Release* HU: Gedeon Richter, 2Q Earnings Release* CZ: Komercni Banka, 2Q Earnings Release* Tuesday, 04/08/2020 AT: AT&S, 1Q Earnings Release* Wednesday, 05/08/2020 PL: Bank Pekao SA, 2Q Earnings Release* PL: Kety, 2Q Earnings Release AT: Lenzing, 2Q Earnings Release* HU: Magyar Telekom, 2Q Earnings...

RICHTER GEDEON PLC. with less fundamental stars is reduced to Neutral

RICHTER GEDEON PLC. (DE), a company active in the Pharmaceuticals industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 3 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date February 28, 2020, the closing price was EUR 18.45 and its expected value was estimated at EUR...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch